“Despite advancements in the treatment of pediatric PsO and active PsA, there continues to be a significant gap in available therapies for these debilitating immune-mediated diseases,” study investigator Vimal Hasmukh Prajapati, MD, clinical associate professor at the University of Calgary said in the news release. He added that guselkumab provides physicians, parents, and caregivers with a proven treatment capable of improving the signs and symptoms of disease.1Guselkumab is a fully human, dual-acting monoclonal antibody that obstructs IL-23 and attaches to the CD64 receptor on IL-23–producing cells, according to Johnson & Johnson. The biologic is effective in treating psoriasis and PsA, as blocking the IL-23 pathway reduces inflammation and the progression of the diseases. The FDA has also approved guselkumab for adults with ulcerative colitis and Crohn disease, making it the first IL-23 inhibitor with both intravenous and subcutaneous administration options.1The pediatric approval was primarily based on results from the phase 3 PROTOSTAR trial (NCT03451851), which evaluated guselkumab in children with moderate to severe plaque PsO.1-3 At week 16, guselkumab demonstrated significantly higher rates of response compared with placebo. Approximately 56% of patients achieved Psoriasis Area and Severity Index (PASI) 90, compared with about 16% of placebo recipients (P < .01).